Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients (MOODBOOSTER)

This randomised, quadruple-blind, placebo-controlled Phase III trial (n=60) will study the early effects of ketamine compared to placebo as an adjunctive therapy with venlafaxine in inpatients with severe unipolar major depressive disorder (MDD).

Participants will receive three doses of intravenous ketamine (35mg/70kg) or a placebo, alongside standard venlafaxine treatment over a week.

The study, sponsored by Assistance Publique – Hôpitaux de Paris, aims to evaluate the rapid efficacy of ketamine in reducing depressive symptoms, as measured by the Hamilton Depression Rating Scale (HDRS). It will also assess biomarkers, synaptic density variations via PET-MRI, and the correlation between ketamine’s efficacy and synaptogenesis.

The trial will take place across three locations in France and is expected to begin in September 2024, with completion anticipated by April 2026.

Topic Depression
Compound Placebo Ketamine
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.